Tobramycin Injectable (iv, Im) Generics - Manufacturers & Suppliers
Bethkis, Tobi (US)
| Product/Composition:- | Tobramycin Injectable (IV, IM) |
|---|---|
| Strength:- | 10 mg/mL, 40 mg/mL, 80 mg/mL |
| Form:- | Injectable (IV, IM) |
| Reference Brands:- | Bethkis, Tobi (US) |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
Tobramycin inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing faulty protein production and bacterial death. It is effective against serious gram-negative infections, including Pseudomonas. Benefits include rapid bacterial eradication, broad-spectrum activity, and suitability for severe infections in hospital settings, when used under proper supervision.
Tobramycin injectable is approved in the EU and US for severe gram-negative bacterial infections, including Pseudomonas aeruginosa. In the EU, brands like Tobramycin are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data; generic formulations are available. Both regions require detailed dossiers, including clinical trial results, quality control, and pharmacovigilance plans for approval and ongoing safety monitoring. Due to its potent activity and toxicity risks, strict prescribing, administration protocols, and monitoring are enforced. For expert regulatory support and dossier management, visit PharmaTradz. We ensure seamless market access, adhering to European and US standards for safe, effective antimicrobial therapy.